证券记录 · 已归档季度
NKTR
Nektar Therapeutics · Healthcare · Biotechnology
12被追踪持有人
-1Δ持有人
3.08M持有股份
$79.53M报告持仓市值
+1新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -7.7% ·
股份流向 -30.0% ·
净新建仓位 -8.3%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +13 | 18.28M | $1.28B | +22 | −8 |
| Q1 2026 | 67 | +13 | 13.34M | $957.94M | +15 | −3 |
| Q4 2025 | 55 | +1 | 8.38M | $354.26M | +2 | — |
| Q3 2025 | 15 | 0 | 5.00M | $284.66M | +2 | −2 |
| Q2 2025 | 12 | -1 | 3.08M | $79.53M | +1 | −2 |
| Q1 2025 | 10 | -1 | 25.55M | $17.36M | — | −1 |
| Q4 2024 | 11 | 0 | 24.86M | $23.13M | — | — |
| Q3 2024 | 10 | +2 | 27.79M | $36.10M | +2 | — |
| Q2 2024 | 8 | — | 27.40M | $33.98M | — | — |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 729.49K | — | $18.85M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | The Vanguard Group ✦ (被动) | 729.49K | — | $18.85M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 649.03K | +325.4% | $16.77M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | BlackRock ✦ (被动) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | PRIMECAP Management ✦ | 299.72K | -16.0% | $7.74M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 247.06K | -21.2% | $6.38M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Geode Capital Management ✦ (被动) | 132.37K | -50.5% | $3.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Geode Capital Management ✦ (被动) | 132.37K | -50.5% | $3.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 79.39K | -17.0% | $2.05M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | State Street Global Advisors ✦ (被动) | 50.10K | -76.9% | $1.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 17.80K | +4.1% | $460,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Fidelity (FMR) ✦ | 15.28K | — | $394,732 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 14.20K | 新增 | $366,928 | 0.0% | New | 1 | SEC ↗ |
| 24 | Marshall Wace ✦ | 14.20K | 新增 | $366,928 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $366,928 | 0.0% |
| Marshall Wace | $366,928 | 0.0% |
已清仓
| Citadel Advisors | $334,013 | 曾为 0.0% |
| D. E. Shaw & Co. | $78,329 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 13.40K 股份, $964 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 18
ROBIN HOWARD W
Officer, Director · 418 股 · $30,088
Aug 18
Zalevsky Jonathan
Officer · 186 股 · $13,388
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A — Two Seas Capital LP
Aug 14
SC 13G/A — BIOTECHNOLOGY VALUE FUND L P
Jul 31
SC 13G — VANGUARD CAPITAL MANAGEMENT LLC
Jul 29
SC 13G — BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据